Saphnelo Can Stave Off Organ Damage From Lupus
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Feb. 19, 2025 -- Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation.
But a newer lupus drug appears to protect patients from much of this organ damage, a new study suggests.
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study published this month in the Annals of the Rheumatic Diseases.
“Anifrolumab plus standard of care (SOC) is effective at reducing organ damage accumulation and prolonging time to organ damage progression compared to SOC alone over 4 years,” a team led by Dr. Zahi Touma, an associate professor of medicine at the University of Toronto, concluded.
People with lupus are typically treated using a combination of inflammation-quelling meds like steroids, antimalarials, immunosuppressants and nonsteroidal anti-inflammatory drugs, researchers said in background notes
But these drugs don't stop organ damage from lupus, and in some cases might even contribute to it, researchers said.
They decided to see if a newer drug, anifrolumab, might better help prevent organ damage if added to the existing brew used to treat lupus patients.
The U.S. Food and Drug Administration (FDA) approved anifrolumab in 2021 for treatment of systemic lupus erythematosus, the most common form of lupus.
Anifolumab Is a monoclonal antibody that works by blocking the receptors for type 1 interferon, a biochemical that plays a key role in promoting inflammation, researchers said.
It’s given once a month via an IV drip, according to Drugs.com.
For the trial, researchers compared 354 patients prescribed anifrolumab against 561 patients who received the usual care for lupus. All of these patients participated in the clinical trials that led to anifrolumab’s approval in the U.S.
Results showed that people taking anifrolumab scored about 0.43 points lower on an index tracking organ damage caused by lupus.
A 1-point increase in that index has previously been associated with a 34% increase in a lupus patient’s risk of premature death, researchers noted.
Anifrolumab patients also had a 61% lower risk of having their organ damage get worse, results show.
The study was paid for by AstraZeneca, which manufactures Saphnelo.
Sources
- Annals of the Rheumatic Diseases, Feb. 1, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Duke Doctors Perform First Living Mitral Valve Transplant
MONDAY, March, 3, 2025 -- In a groundbreaking series of surgeries, doctors at Duke Health have successfully performed the world’s first living mitral valve replacement...
Rewards of Tight Blood Pressure Control Outweigh Risks, Trial Finds
FRIDAY, Feb. 21, 2025 -- The health benefits of aggressive blood pressure control outweigh the potential risks for seniors, according to the latest results from a major clinical...
Epstein-Barr Virus Might Help Trigger Cancer After Kidney Transplant
Key Takeaways Kidney transplant recipients who’ve never been exposed to the Epstein-Barr virus but receive organs from a donor who has been may develop a rare and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.